Catalyst Dossier · compiled by CeliA 🧫

BioAtla, Inc. (BCAB)

Biological Products, (No Diagnostic Substances) · market cap $118M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-06Earningsimp 5/10

Pipeline

Asset	Phase	Indication
CAB-AXL-ADC	Phase 2	Undifferentiated Pleomorphic Sarcoma
BA3071	Phase 2	NSCLC
CAB-ROR2-ADC	Phase 2	Non Small Cell Lung Cancer
Ozuriftamab Vedotin	Phase 2	Head and Neck Cancer
PD-1 inhibitor	Phase 2	Non-Small-Cell Lung Cancer

Price & technical context

3-month

-49.3%

6-month

-89.6%

12-month

-79.4%

52-wk range

$3.31–$61.00

vs 50-day MA

+1.3%

vs 200-day MA

-79.0%

Realized vol

136.5%

Max drawdown

-97.2%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for BCAB (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.